| RRC ID |
65417
|
| 著者 |
Shimura K, Mabuchi S, Komura N, Yokoi E, Kozasa K, Sasano T, Kawano M, Matsumoto Y, Watabe T, Kodama M, Hashimoto K, Sawada K, Hatazawa J, Kimura T.
|
| タイトル |
Prognostic significance of bone marrow FDG uptake in patients with gynecological cancer.
|
| ジャーナル |
Sci Rep
|
| Abstract |
We investigated the prognostic significance and the underlying mechanism of increased bone marrow (BM) 2-(18F) fluoro-2-deoxy-D-glucose as a tracer (FDG)-uptake in patients with gynecological cancer. A list of patients diagnosed with cervical, endometrial, and ovarian cancer from January 2008 to December 2014 were identified. Then, through chart reviews, 559 patients who underwent staging by FDG-positron emission tomography (PET)/computed tomography (CT) and subsequent surgical resection were identified, and their clinical data were reviewed retrospectively. BM FDG-uptake was evaluated using maximum standardized uptake value (SUVmax) and BM-to-aorta uptake ratio (BAR). As a result, we have found that increased BAR was observed in 20 (8.7%), 21 (13.0%), 21 (12.6%) of cervical, endometrial, and ovarian cancer, respectively, and was associated with significantly shorter survival. Increased BAR was also closely associated with increased granulopoiesis. In vitro and in vivo experiments revealed that tumor-derived granulocyte colony-stimulating factor (G-CSF) was involved in the underlying causative mechanism of increased BM FDG-uptake, and that immune suppression mediated by G-CSF-induced myeloid-derived suppressor cells (MDSCs) is responsible for the poor prognosis of this type of cancer. In conclusion, increased BM FDG-uptake, as represented by increased BAR, is an indicator of poor prognosis in patients with gynecological cancer.
|
| 巻・号 |
11(1)
|
| ページ |
2257
|
| 公開日 |
2021-1-26
|
| DOI |
10.1038/s41598-021-81298-1
|
| PII |
10.1038/s41598-021-81298-1
|
| PMID |
33500424
|
| PMC |
PMC7838412
|
| MeSH |
Adult
Aged
Aged, 80 and over
Animals
Aorta / metabolism
Bone Marrow / metabolism*
Cell Line, Tumor
Female
Fluorodeoxyglucose F18 / pharmacokinetics*
Genital Neoplasms, Female / diagnostic imaging
Genital Neoplasms, Female / metabolism*
Granulocyte Colony-Stimulating Factor / metabolism
Humans
Mice, Inbred C57BL
Middle Aged
Multivariate Analysis
Myeloid-Derived Suppressor Cells / metabolism
Positron Emission Tomography Computed Tomography
Prognosis
Progression-Free Survival
Rats
|
| IF |
3.998
|
| リソース情報 |
| 遺伝子材料 |
pCAmGCSF (RDB04277)
pCAZ 2 (RDB01870) |
